Table 3.

Virologic Response During and After Therapy

Response	Sofosbuvir-Ribavirin for 12 Weeks (N = 17)
HCV RNA < LLOQ TND
On therapy, n (%)
Week 1	2 (12)
Week 2	5 (29)
Week 4	12 (71)
Week 8	17 (100)
End of therapy (week 12), n (%)	17 (100)
After end of therapy, n (%)
Week 2 (SVR2)	8 (57)a
Week 4 (SVR4)	10 (59)
Week 12 (SVR12)	10 (59)b
Virologic breakthrough during treatment	0
Relapse in patients with HCV RNA < LLOQ TND at end of therapy	7 (41)

Abbreviations: HCV, hepatitis C virus; LLOQ, lower limit of quantification; SVR, sustained virologic response; TND, target not detected.

^aThree participants missed the week 2 visit (N = 14).

^bOne participant missed the end-of-therapy week 12 visit but had detectable HCV RNA at the end of treatment week 4 visit and thus is counted as a relapse based on preceding result.